Saturday, November 22, 2008
Latest Procurement News
SPONSORED LINKS
- Bridging the gap: Achieving high performance in product portfolio management
- Where cost meets control: Applying global fulfillment to enable high performance
- Supply chain management process: Supply chain strategy solutions from Accenture
- Creating an effective China "Cold Supply Chain"
- It takes two: Converging product development and procurement helps companies achieve high performance
- Supply chain management: How to build a successful global operations model
RELATED NEWS
- Chinese government goes to work on employment concerns
21 Nov 08 - Scramble for supply could ignite global conflict
21 Nov 08 - Rolls-Royce announces fresh job cuts
20 Nov 08 - Hershey wraps-up new appointment
18 Nov 08 - Renault announces tightening of supply chain
18 Nov 08 - Insurance u-turn puts brakes on troubled US car industry
14 Nov 08
RELATED ARTICLES
- Proactive approach to risk management opens door to salvation
- Scarce supplies and a local emphasis - welcome to 2016
- Opinion: False sense of security
- Disappearing acts
- Bottom of the Barrel
- Big Blue's Red adventure
KNOWLEDGE MANAGEMENT TAGS
"Supply Chain Management", "Risk Management"
European pharma supply chain in need of health check
The European pharmaceutical industry must step up its efforts to ensure that illegal and fake drugs do not enter the supply chain, a new study has warned.
Using data gathered from 250,000 prescriptions issued in Greece and Belgium this summer, academics working with Aegate, a drugs safety company, found that almost one per cent of the drugs requests had been recalled by regulators, and should not have been on sale and available to patients.
The findings are likely to place further pressure on the European Union to implement a new Europe-wide drug distribution strategy to ensure that unauthorised drugs do not find their way into the supply chain.
Despite the findings, Gary Noon, chief executive of Aegate, said that the data was not sufficiently robust to draw any firm conclusions about the prevalence of counterfeit medicine within the European Union, arguing that the sample size was too small.
= Online Global Members Only 
= Premier Members Only
